Matthew German, MD
Infectious Disease · Chesterfield, MONPI 1073628871
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 777 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by Viiv Healthcare Company at 25.5% of the total. Among infectious disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 777 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$2K
- AbbVie$2K
- Merck$1K
- Johnson & Johnson$943
- Amgen$392
- plus $6K from 54 others
What the payments were for
- Speaking & faculty fees$1531%
- Food & beverage$15,73198%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$1,319
- Mavyret$240
- EMBLAVEO$125
- Biktarvy$125
- Sunlenca$121
- CABENUVA$115
- VA-LCP PLATES & SCREWS$108
- DCP/LC-DCP PLATES & SCREWS$108
- BME NITINOL CONTINUOUS COMPRESSION IMPLANTS$108
- Alinity m$106
How this compares
$16,085 in reported general payments places this provider in the 95th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 278 | $1,190,509 |
| DovatoDolutegravir Sodium/Lamivudine | 207 | $709,689 |
| RukobiaFostemsavir Tromethamine | 21 | $216,217 |
| TivicayDolutegravir Sodium | 65 | $168,785 |
| PrezcobixDarunavir/Cobicistat | 47 | $122,529 |
| JulucaDolutegravir/Rilpivirine | 27 | $109,126 |
| PifeltroDoravirine | 29 | $67,737 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 17 | $67,599 |
| MytesiCrofelemer | 12 | $34,078 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 12 | $31,960 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $24,298 |
| OzempicSemaglutide | 25 | $23,305 |
| WegovySemaglutide | 12 | $22,342 |
| Daptomycin | 12 | $21,655 |
| EdurantRilpivirine Hcl | 13 | $20,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $2,274 | $1,214,807289 claims |
| Viiv Healthcare CompanyDovato, Rukobia, Tivicay, Juluca | $4,104 | $1,203,818320 claims |
| Johnson & JohnsonPrezcobix | $943 | $122,52947 claims |
| MerckPifeltro, Delstrigo, Januvia | $1,084 | $106,15652 claims |
| Novo NordiskOzempic, Wegovy | $35 | $45,64737 claims |
| Napo Pharmaceuticals IncMytesi | $329 | $34,07812 claims |
| Janssen Scientific Affairs, LLCEdurant | $139 | $20,08513 claims |
| Lilly USA, LLCTrulicity | $115 | $15,18314 claims |
| PfizerEliquis | $287 | $15,09218 claims |
| Boehringer IngelheimJardiance | $45 | $10,83421 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $5,88412 claims |
| AstraZenecaNexium | $182 | $2,97811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Chesterfield
- Nirmol PhilipChesterfield$31K
- John CampbellChesterfield$11K
- Joseph FritzChesterfield$4K
- David McCraryChesterfield$3K
- Leon RobisonChesterfield$1K
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Andrej SpecSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.